Skip to main content

Artery Disease in Psoriasis Tied to LOX-1 Levels

Soluble lectinlike oxidized low-density lipoprotein receptor-1 (sLOX-1) levels are likely elevated in patients with psoriasis and associated with disease severity, according to the findings of a recent study.

Psoriasis is known to be associated with accelerated noncalcified coronary burden (NCB) and accelerated lipoprotein oxidation. “A transmembrane scavenger receptor for these oxidized modified lipoproteins is LOX-1, which has been reported to be associated with coronary artery disease,” the researchers said. “It is unknown whether this receptor is associated with coronary artery disease in psoriasis.”
_________________________________________________
Related content

Exploring Psoriasis and Cardiovascular Comorbidity
Does Body Weight Affect Psoriasis Risk?
_________________________________________________

Findings from a recent study showed the potential role of lectinlike oxidized low-density lipoprotein receptor-1 (LOX-1) in noncalcified coronary burden among patients with psoriasis.

To examine this potential association further, the researchers assessed the association between sLOX-1 and NCB among 175 patients with psoriasis referred to outpatient dermatology practices between January 1, 2013 and October 1, 2017. In addition, 138 patients with psoriasis were followed up at 1 year. Circulating sLOX-1 levels were measured using an enzyme-linked immunosorbent assay, and coronary computed tomography angiography scans were used to quantify NCB in all 3 major epicardial coronary arteries.

Among the 175 patients, the researchers found relatively low median cardiovascular risk by Framingham risk score and a mean body mass index suggestive of overweight profiles.

Patients with psoriasis had elevated sLOX-1 levels compared with age- and sex-matched controls, the researchers said. These levels were associated with Psoriasis Area and Severity Index (PASI) score.

In addition, the researchers found sLOX-1 was associated with NCB independent of hyperlipidemia status and was persistent after adjusting for traditional cardiovascular risk factors, statin use, and biologic psoriasis treatment.

At 1 year, clinical improvement in PASI was associated with reduction in sLOX-1, which was associated with a reduction in NCB, the researchers said. This finding suggests a potential role of this lipid protein in inflammatory atherogenesis in psoriasis, they noted.

These findings suggest that reductions of sLOX-1 level at 1 year are associated with improvements in patients with psoriasis,” the researchers concluded.

Reference

Dey AK, Gaddipati R, Elnabawi YA, et al. Association between soluble lectinlike oxidized low-density lipoprotein receptor-1 and coronary artery disease in psoriasis [published online November 20, 2019].  JAMA Dermatol. doi:10.1001/jamadermatol.2019.3595

 

Back to Top